青年成人颅内动脉瘤:手术与血管内治疗结局
本研究回顾分析了2001年1月至2015年12月间接受显微手术或血管内治疗的276例青年成人(20-39岁)315个囊性颅内动脉瘤,主要结局为主要复发和治疗相关并发症。主要复发21例(6.7%),血管内治疗、破裂动脉瘤、 younger age和大小是独立相关因素;治疗相关并发症5例(1.6%),两组无差异。作者认为两种方法均安全,显微手术耐久性更好,鉴于青年患者预期寿命更长,可能优于血管内治疗。
要点
- 主要复发21例(6.7%),血管内治疗(aHR 7.21)与破裂动脉瘤(aHR 6.44)等为独立相关因素。
- 治疗相关并发症5例(1.6%),显微手术组与血管内治疗组无显著差异(P > 0.999)。
- 蛛网膜下腔出血患者中不良功能结局(mRS ≥2)30例(19.6%),仅Hunt和Hess分级独立相关。
核心结论
- 显微手术和血管内治疗用于青年成人颅内动脉瘤均是安全的。
- 显微手术显示出更好的治疗耐久性,鉴于青年患者较老年患者预期寿命更长,可能优于血管内治疗。
研究设计与样本
- 研究纳入2001年1月至2015年12月间接受显微手术或血管内治疗的276例青年成人(20-39岁)患者,共315个囊性颅内动脉瘤。
- 主要结局指标为主要复发和治疗相关并发症,同时评估蛛网膜下腔出血患者的功能结局。
主要发现
- 主要复发发生于21例(6.7%)。
- 较年轻年龄(aHR 3.77;95%CI 1.45-9.83;P = 0.007)、破裂动脉瘤(aHR 6.44;95%CI 2.09-19.89;P = 0.001)、大小(aHR 1.84;95%CI 1.06-3.18;P = 0.030)和血管内治疗(aHR 7.21;95%CI 2.44-21.35;P < 0.001)与主要复发独立相关。
- 治疗相关并发症发生于5例(1.6%),显微手术组与血管内治疗组间无显著差异(P > 0.999)。
- 蛛网膜下腔出血患者中不良结局(改良Rankin量表评分≥2)见于30例(19.6%),仅Hunt和Hess分级与不良功能结局独立相关。
临床怎么用
- 作者认为,显微手术和血管内治疗用于青年成人颅内动脉瘤均是安全的。
- 作者认为,鉴于青年患者预期寿命更长,显微手术可能优于血管内治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite its relative rarity, the potential for loss of productive years makes aneurysmal subarachnoid hemorrhage (SAH) a considerably important entity in young adult patients (20-39 years of age). This study aimed to analyze outcomes of microsurgery (MS) and endovascular treatment (EVT) for saccular intracranial aneurysms (IAs) in young adult patients. METHODS: A total of 276 young adult patients with 315 IAs, treated with MS or EVT between January 2001 and December 2015, were studied. Major recurrence and treatment-related complications were the primary outcome measures. Functional outcomes in patients with SAH were also assessed. RESULTS: Major recurrence occurred in 21 cases (6.7%). Younger age (adjusted hazard ratio [aHR], 3.77; 95% confidence interval [CI], 1.45-9.83; P = 0.007), ruptured IA (aHR, 6.44; 95% CI, 2.09-19.89; P = 0.001), size (aHR, 1.84; 95% CI, 1.06-3.18; P = 0.030), and EVT (aHR, 7.21; 95% CI, 2.44-21.35; P < 0.001) were independently related to major recurrence. Treatment-related complications occurred in 5 cases (1.6%) and did not differ between the MS and EVT groups (P > 0.999). Unfavorable outcomes (modified Rankin scale score ≥2) were identified in 30 patients (19.6%) with SAH, and only Hunt and Hess grade was independently associated with unfavorable functional outcome. CONCLUSIONS: Both MS and EVT are safe for treating IAs in young adult patients. MS showed better durability of treatment and may be preferred over EVT in young patients in view of their longer life expectancy compared with older patients.
引用
- Jee TK, Nam TM, Yeon JY, et al. Intracranial Aneurysms in Young Adult Patients: Surgical and Endovascular Treatment Outcomes. World Neurosurg. 2019. PMID: 31899407. doi:10.1016/j.wneu.2019.12.124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。